TY  - JOUR
AU  - Schmid, Sabine
AU  - Jiang, Mei
AU  - Brown, M Catherine
AU  - Fares, Aline
AU  - Garcia, Miguel
AU  - Soriano, Joelle
AU  - Dong, Mei
AU  - Thomas, Sera
AU  - Kohno, Takashi
AU  - Leal, Leticia Ferro
AU  - Diao, Nancy
AU  - Xie, Juntao
AU  - Wang, Zhichao
AU  - Zaridze, David
AU  - Holcatova, Ivana
AU  - Lissowska, Jolanta
AU  - Świątkowska, Beata
AU  - Mates, Dana
AU  - Savic, Milan
AU  - Wenzlaff, Angela S
AU  - Harris, Curtis C
AU  - Caporaso, Neil E
AU  - Ma, Hongxia
AU  - Fernandez-Tardon, Guillermo
AU  - Barnett, Matthew J
AU  - Goodman, Gary
AU  - Davies, Michael P A
AU  - Pérez-Ríos, Mónica
AU  - Taylor, Fiona
AU  - Duell, Eric J
AU  - Schoettker, Ben
AU  - Brenner, Hermann
AU  - Andrew, Angeline
AU  - Cox, Angela
AU  - Ruano-Ravina, Alberto
AU  - Field, John K
AU  - Marchand, Loic Le
AU  - Wang, Ying
AU  - Chen, Chu
AU  - Tardon, Adonina
AU  - Shete, Sanjay
AU  - Schabath, Matthew B
AU  - Shen, Hongbing
AU  - Landi, Maria Teresa
AU  - Ryan, Brid M
AU  - Schwartz, Ann G
AU  - Qi, Lihong
AU  - Sakoda, Lori C
AU  - Brennan, Paul
AU  - Yang, Ping
AU  - Zhang, Jie
AU  - Christiani, David C
AU  - Reis, Rui Manuel
AU  - Shiraishi, Kouya
AU  - Hung, Rayjean J
AU  - Xu, Wei
AU  - Liu, Geoffrey
TI  - Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data.
JO  - Cancer epidemiology, biomarkers & prevention
VL  - 31
IS  - 3
SN  - 1055-9965
CY  - Philadelphia, Pa.
PB  - AACR
M1  - DKFZ-2022-00486
SP  - cebp.0747.2021 -
PY  - 2022
AB  - Somatic EGFR mutations define a subset of non-small cell lung cancers (NSCLC) that have clinical impact on NSCLC risk and outcome. However, EGFR-mutation-status is often missing in epidemiologic datasets. We developed and tested pragmatic approaches to account for EGFR-mutation-status based on variables commonly included in epidemiologic datasets and evaluated the clinical utility of these approaches.Through analysis of the International Lung Cancer Consortium (ILCCO) epidemiologic datasets, we developed a regression model for EGFR-status; we then applied a clinical-restriction approach using the optimal cut-point, and a second epidemiologic, multiple imputation approach to ILCCO survival analyses that did and did not account for EGFR-status.Of 35,356 ILCCO patients with NSCLC, EGFR-mutation-status was available in 4,231 patients. A model regressing known EGFR-mutation-status on clinical and demographic variables achieved a concordance index of 0.75 (95
LB  - PUB:(DE-HGF)16
C6  - pmid:35027437
DO  - DOI:10.1158/1055-9965.EPI-21-0747
UR  - https://inrepo02.dkfz.de/record/179129
ER  -